Patents Assigned to SYDNEXIS, INC.
-
Patent number: 11896588Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, Wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: November 16, 2022Date of Patent: February 13, 2024Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
-
Patent number: 11890277Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: November 16, 2022Date of Patent: February 6, 2024Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
-
Patent number: 11883390Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: November 16, 2022Date of Patent: January 30, 2024Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
-
Patent number: 11596625Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: November 13, 2020Date of Patent: March 7, 2023Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
-
Patent number: 11382909Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: November 7, 2019Date of Patent: July 12, 2022Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker, Harun Takruri
-
Patent number: 11052094Abstract: Provided herein is an ophthalmic composition formulated in deuterated water. Also disclosed herein are methods of treating, ameliorating, or reducing ophthalmic conditions or diseases by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: May 27, 2016Date of Patent: July 6, 2021Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
-
Patent number: 11052095Abstract: Provided herein is an ophthalmic composition formulated in deuterated water. Also disclosed herein are methods of treating, ameliorating, or reducing ophthalmic conditions or diseases by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: February 28, 2020Date of Patent: July 6, 2021Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
-
Patent number: 10953002Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: February 7, 2020Date of Patent: March 23, 2021Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker, Harun Takruri
-
Patent number: 10940145Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: February 7, 2020Date of Patent: March 9, 2021Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker, Harun Takruri
-
Patent number: 10888557Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: February 7, 2020Date of Patent: January 12, 2021Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker, Harun Takruri
-
Patent number: 10864208Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: December 18, 2018Date of Patent: December 15, 2020Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
-
Patent number: 10842787Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: April 25, 2016Date of Patent: November 24, 2020Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker, Harun Takruri
-
Patent number: 10813923Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: June 22, 2020Date of Patent: October 27, 2020Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker, Harun Takruri
-
Patent number: 10201534Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: February 13, 2018Date of Patent: February 12, 2019Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
-
Patent number: 10076515Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: July 27, 2017Date of Patent: September 18, 2018Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
-
Patent number: 9770447Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: July 12, 2016Date of Patent: September 26, 2017Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
-
Patent number: 9421199Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: May 29, 2015Date of Patent: August 23, 2016Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker